APTOF · Aptose Biosciences Inc. · Executive Compensation
$1.69
+0.00 (+0.00%)
At close · Jul 3
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The aforementioned conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$4.31M
Shares
2.55M
Volume · Jul 3
426
Avg daily vol (2 sessions)
531
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| all of the directors of the Company | directors | Resigned | 2026-07-01 |
| Carol Ashe | member of the Board | Resigned | 2025-06-18 |
| Dr. Bernd R. Seizinger | Board of Directors | Appointed | 2022-09-16 |